Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Dongrui Pharmaceutical ( 02348.HK ) Net loss for 2025 decreases by 62.1% to 2.14 billion yuan
Gelonghui, March 29丨Dongrui Pharmaceutical (02348.HK) announced its annual results. For the fiscal year 2024, the group recorded revenue of approximately RMB 1.231 billion, an increase of about 16.1% compared to 2024. Profit attributable to the owners of the parent company was approximately RMB 214 million, a decrease of 62.1% from 2024. This was due to the net gain of approximately RMB 278 million from the sale of a 35% stake in Kangrong Oriental, which had a book value of zero; excluding the above non-recurring profit of approximately RMB 367 million and the loss of RMB 3.696 million attributable to Kangrong Oriental prior to the sale of the equity, the operating profit attributable to the owners of the parent company for 2024 was RMB 202 million, representing an increase of 6.1% from 2025 compared to 2024. A final dividend of HKD 0.048 per share is proposed.